Oral administration of (±)3,4-methylenedioxymethamphetamine and (+)methamphetamine alters temperature and activity in rhesus macaques

Pharmacology Biochemistry and Behavior

Volumn 87, Issue 1, 2007, Pages 11-19

  Crean, Rebecca D ^a   Davis, Sophia A ^a   Taffe, Michael A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Amphetamine; Circadian; Ecstasy; Macaca mulatta; Neurotoxicity; Serotonin; Thermoregulation

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALCOHOL; AMPHETAMINE; DRONABINOL; KETAMINE; MECAMYLAMINE; METHAMPHETAMINE; METHYLPHENIDATE; NICOTINE; RACLOPRIDE; SCOPOLAMINE; CENTRAL STIMULANT AGENT; SEROTONIN RECEPTOR AFFECTING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; BODY TEMPERATURE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DRUG ABUSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MEGADOSE; HYPERTHERMIA; LOCOMOTION; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RECTUM TEMPERATURE; RHESUS MONKEY; TELEMETRY; TEMPERATURE MEASUREMENT; THERMOREGULATION; ANIMAL; INTRAMUSCULAR DRUG ADMINISTRATION; MACACA; MOTOR ACTIVITY; ORAL DRUG ADMINISTRATION; STATISTICAL ANALYSIS; STEREOISOMERISM;

ANIMALIA; MACACA MULATTA; PRIMATES;

ADMINISTRATION, ORAL; ANIMALS; BODY TEMPERATURE; BODY TEMPERATURE REGULATION; CENTRAL NERVOUS SYSTEM STIMULANTS; DATA INTERPRETATION, STATISTICAL; INJECTIONS, INTRAMUSCULAR; MACACA MULATTA; MALE; METHAMPHETAMINE; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SEROTONIN AGENTS; STEREOISOMERISM; TELEMETRY;

EID: 34249857825     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2007.03.015     Document Type: Article

References (84)

1. Baggott M., Heifets B., Jones R.T., Mendelson J., Sferios E., and Zehnder J. Chemical analysis of ecstasy pills. JAMA 284 (2000) 2190
2. Ball J., Garfield T., Morin C., and Steele D. Emergency Department Trends from the Drug Abuse Warning Network, Final Estimates 1995-2002. DAWN Series D-24, DHHS Publication No. (SMA) 03-3780 (2003), Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Rockville, MD
3. Ball J., Morin C., Cover E., Green J., Sonnefeld J., Steele D., et al. Drug Abuse Warning Network, 2003: Interim National Estimates of Drug-Related Emergency Department Visits. DAWN Series D-26, DHHS Publication No. (SMA) 04-3972 (2004), Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Rockville, MD
4. Bishop C., Taylor J.L., Kuhn D.M., Eskow K.L., Park J.Y., and Walker P.D. MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. Eur J Neurosci 23 (2006) 2669-2676
5. Blessing W.W., Seaman B., Pedersen N.P., and Ootsuka Y. Clozapine reverses hyperthermia and sympathetically mediated cutaneous vasoconstriction induced by 3,4-methylenedioxymethamphetamine (ecstasy) in rabbits and rats. J Neurosci 23 (2003) 6385-6391
6. Bowyer J.F., Tank A.W., Newport G.D., Slikker Jr. W., Ali S.F., and Holson R.R. The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J Pharmacol Exp Ther 260 (1992) 817-824
7. Bowyer J.F., Davies D.L., Schmued L., Broening H.W., Newport G.D., Slikker Jr. W., et al. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther 268 (1994) 1571-1580
8. Bowyer J.F., Young J.F., Slikker W., Itzak Y., Mayorga A.J., Newport G.D., et al. Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations. Neurotoxicology 24 (2003) 379-390
9. Brown P.L., and Kiyatkin E.A. Brain hyperthermia induced by MDMA (ecstasy): modulation by environmental conditions. Eur J Neurosci 20 (2004) 51-58
10. Buffum J.C., and Shulgin A.T. Overdose of 2.3 grams of intravenous methamphetamine: case, analysis and patient perspective. J Psychoactive Drugs 33 (2001) 409-412
11. Carvalho M., Carvalho F., Remiao F., de Lourdes Pereira M., Pires-das-Neves R., and de Lourdes Bastos M. Effect of 3,4-methylenedioxymethamphetamine ("ecstasy") on body temperature and liver antioxidant status in mice: influence of ambient temperature. Arch Toxicol 76 (2002) 166-172
12. Clark J.D., Baldwin R.L., Bayne K.A., Brown M.J., Gebhart G.F., Gonder J.C., et al. Guide for the care and use of laboratory animals (1996), Institute of Laboratory Animal Resources, National Research Council, Washington D.C. 125
13. Clemens K.J., Van Nieuwenhuyzen P.S., Li K.M., Cornish J.L., Hunt G.E., and McGregor I.S. MDMA ("ecstasy"), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat. Psychopharmacology (Berl) 173 (2004) 318-325
14. Clemens K.J., Cornish J.L., Li K.M., Hunt G.E., and McGregor I.S. MDMA ('Ecstasy') and methamphetamine combined: order of administration influences hyperthermic and long-term adverse effects in female rats. Neuropharmacology 49 (2005) 195-207
15. Clemens K.J., Cornish J.L., Hunt G.E., and McGregor I.S. Repeated weekly exposure to MDMA, methamphetamine or their combination: long-term behavioural and neurochemical effects in rats. Drug Alcohol Depend 86 2-3 (2007 Jan 12) 183-190 [Electronic publication ahead of print 2006 Aug 1]
16. Clingerman K.J., and Summers L. Development of a body condition scoring system for nonhuman primates using Macaca mulatta as a model. Lab Anim (NY) 34 (2005) 31-36
17. Cole J.C., Bailey M., Sumnall H.R., Wagstaff G.F., and King L.A. The content of ecstasy tablets: implications for the study of their long-term effects. Addiction 97 (2002) 1531-1536
18. Crean R.D., Davis S.A., Von Huben S.N., Lay C.C., Katner S.N., and Taffe M.A. Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques. Neuroscience 142 (2006) 515-525
19. Dafters R.I. Effect of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") in rats. Psychopharmacology (Berl) 114 (1994) 505-508
20. Dams R., De Letter E.A., Mortier K.A., Cordonnier J.A., Lambert W.E., Piette M.H., et al. Fatality due to combined use of the designer drugs MDMA and PMA: a distribution study. J Anal Toxicol 27 (2003) 318-322
21. Doblin R. MAPS-sponsored cancer anxiety research. MAPS Bull 16 (2006) 11
22. EcstasyData.org. EcstasyData.org: Ecstasy Lab Testing & Analysis Results - Ecstasy Pill Reports. Erowid, Dancesafe, MAPS, & the Promind Foundation, 2006.
23. Fantegrossi W.E., Godlewski T., Karabenick R.L., Stephens J.M., Ullrich T., Rice K.C., et al. Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology (Berl) 166 (2003) 202-211
24. Fantegrossi W.E., Kiessel C.L., Leach P.T., Van Martin C., Karabenick R.L., Chen X., et al. Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice. Psychopharmacology (Berl) 173 (2004) 270-277
25. FDA. Desoxyn®: Methamphetamine Hydrochloride tablets, USP (2001), U. S. Food and Drug Administration, Rockville MD
26. FDA. Adderall XR Capsules (2004), U.S. Food and Drug Administration, Rockville MD
27. Fiege M., Wappler F., Weisshorn R., Gerbershagen M.U., Menge M., and Schulte Am Esch J. Induction of malignant hyperthermia in susceptible swine by 3,4-methylenedioxymethamphetamine ("Ecstasy"). Anesthesiology 99 (2003) 1132-1136
28. Fox H.C., Parrott A.C., and Turner J.J. Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug. J Psychopharmacol 15 (2001) 273-281
29. Freedman R.R., Johanson C.E., and Tancer M.E. Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 183 (2005) 248-256
30. Frith C.H., Chang L.W., Lattin D.L., Walls R.C., Hamm J., and Doblin R. Toxicity of methylenedioxymethamphetamine (MDMA) in the dog and the rat. Fundam Appl Toxicol 9 (1987) 110-119
31. Gillman P.K. Ecstasy, serotonin syndrome and the treatment of hyperpyrexia. Med J Aust 167 (1997) 109-111
32. Gold L.H., and Koob G.F. Methysergide potentiates the hyperactivity produced by MDMA in rats. Pharmacol Biochem Behav 29 (1988) 645-648
33. Gordon C.J., and Fogelson L. Metabolic and thermoregulatory responses of the rat maintained in acrylic or wire-screen cages: implications for pharmacological studies. Physiol Behav 56 (1994) 73-79
34. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., and Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55 (2003) 463-508
35. Green A.R., O'Shea E., and Colado M.I. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol 500 (2004) 3-13
36. Greenhill L.L., Swanson J.M., Steinhoff K., Fried J., Posner K., Lerner M., et al. A pharmacokinetic/pharmacodynamic study comparing a single morning dose of adderall to twice-daily dosing in children with ADHD. J Am Acad Child Adolesc Psychiatry 42 (2003) 1234-1241
37. Henry J.A., Jeffreys K.J., and Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 340 (1992) 384-387
38. Iravani M.M., Jackson M.J., Kuoppamaki M., Smith L.A., and Jenner P. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Neurosci 23 (2003) 9107-9115
39. Johnson G.S., and Elizondo R.S. Thermoregulation in Macaca mulatta: a thermal balance study. J Appl Physiol 46 (1979) 268-277
40. Katner S.N., Davis S.A., Kirsten A.J., and Taffe M.A. Effects of nicotine and mecamylamine on cognition in rhesus monkeys. Psychopharmacology (Berl) 175 (2004) 225-240
41. Katner S.N., Flynn C.T., Von Huben S.N., Kirsten A.J., Davis S.A., Lay C.C., et al. Controlled and behaviorally relevant levels of oral ethanol intake in rhesus macaques using a flavorant-fade procedure. Alcohol Clin Exp Res 28 (2004) 873-883
42. Kelly B.C., Parsons J.T., and Wells B.E. Prevalence and predictors of club drug use among club-going young adults in New York city. J Urban Health 83 (2006) 884-895
43. Levy K.B., O'Grady K.E., Wish E.D., and Arria A.M. An in-depth qualitative examination of the ecstasy experience: results of a focus group with ecstasy-using college students. Subst Use Misuse 40 (2005) 1427-1441
44. Libiseller K., Pavlic M., Grubwieser P., and Rabl W. Ecstasy-deadly risk even outside rave parties. Forensic Sci Int 153 (2005) 227-230
45. Madden L.J., Flynn C.T., Zandonatti M.A., May M., Parsons L.H., Katner S.N., et al. Modeling human methamphetamine exposure in nonhuman primates: chronic dosing in the rhesus macaque leads to behavioral and physiological abnormalities. Neuropsychopharmacology 30 (2005) 350-359
46. Malberg J.E., and Seiden L.S. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 18 (1998) 5086-5094
47. Mallick A., and Bodenham A.R. MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 degrees C. J Accid Emerg Med 14 (1997) 336-338
48. McCabe S.E., Teter C.J., and Boyd C.J. The use, misuse and diversion of prescription stimulants among middle and high school students. Subst Use Misuse 39 (2004) 1095-1116
49. McCabe S.E., Teter C.J., and Boyd C.J. Medical use, illicit use and diversion of prescription stimulant medication. J Psychoactive Drugs 38 (2006) 43-56
50. Mechan A., Yuan J., Hatzidimitriou G., Irvine R.J., McCann U.D., and Ricaurte G.A. Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. Neuropsychopharmacology 31 (2006) 339-350
51. Melian A.M., Burillo-Putze G., Campo C.G., Padron A.G., and Ramos C.O. Accidental ecstasy poisoning in a toddler. Pediatr Emerg Care 20 (2004) 534-535
52. Mithoefer M. MDMA-assisted psychotherapy in the treatment of posttraumatic stress disorder (PTSD): seventh update on study progress. MAPS Bull 16 (2006) 7-8
53. Mithoefer M. Study protocol: Phase II clinical trial testing the safety and efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in subjects with chronic posttraumatic stress disorder (2006), Multidisciplinary Association for Psychedelic Studies. http://www.maps.org/mdma/protocol/index.html http://www.maps.org/mdma/protocol/index.html
54. Mojeiko V. Israel MDMA/PTSD Research Project. MAPS Bull 16 (2006) 10
55. NRC/NAS. Nutrient requirements of nonhuman primates: second revised edition (2003), National Research Council of The National Academy of Sciences, Washington D.C.
56. Oehen P. MDMA-assisted psychotherapy pilot study in Switzerland. MAPS Bull 16 (2006) 9
57. Patel M.M., Belson M.G., Longwater A.B., Olson K.R., and Miller M.A. Methylenedioxymethamphetamine (ecstasy)-related hyperthermia. J Emerg Med 29 (2005) 451-454
58. Pedersen N.P., and Blessing W.W. Cutaneous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits. J Neurosci 21 (2001) 8648-8654
59. Prosser J.M., Naim M., and Helfaer M.A. A 14-year-old girl with agitation and hyperthermia. Pediatr Emerg Care 22 (2006) 676-679
60. Ricaurte G.A., Yuan J., Hatzidimitriou G., Cord B.J., and McCann U.D. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy"). Science 297 (2002) 2260-2263
61. Ricaurte G.A., Yuan J., Hatzidimitriou G., Cord B.J., and McCann U.D. Retraction. Science 301 (2003) 1479
62. Risbrough V.B., Masten V.L., Caldwell S., Paulus M.P., Low M.J., and Geyer M.A. Differential contributions of dopamine D1, D2, and D3 receptors to MDMA-induced effects on locomotor behavior patterns in mice. Neuropsychopharmacology 31 11 (2006 Nov) 2349-2358 [Electronic publication 2006 Jul 19]
63. Rosa-Neto P., Olsen A.K., Gjedde A., Watanabe H., and Cumming P. MDMA-evoked changes in cerebral blood flow in living porcine brain: correlation with hyperthermia. Synapse 53 (2004) 214-221
64. Rusyniak D.E., and Sprague J.E. Toxin-induced hyperthermic syndromes. Med Clin North Am 89 (2005) 1277-1296
65. Saadat K.S., Elliott J.M., Colado M.I., and Green A.R. Hyperthermic and neurotoxic effect of 3,4-methylenedioxymethamphetamine (MDMA) in guinea pigs. Psychopharmacology (Berl) 173 (2004) 452-453
66. Schifano F. Potential human neurotoxicity of MDMA ('Ecstasy'): subjective self-reports, evidence from an Italian drug addiction centre and clinical case studies. Neuropsychobiology 42 (2000) 25-33
67. Sotnikova T.D., Beaulieu J.M., Barak L.S., Wetsel W.C., Caron M.G., and Gainetdinov R.R. Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol 3 (2005) e271
68. Taffe M.A. Effects of parametric feeding manipulations on behavioral performance in macaques. Physiol Behav 81 (2004) 59-70
69. Taffe M.A. Erratum: "Effects of parametric feeding manipulations on behavioral performance in macaques". Physiol Behav 82 (2004) 589
70. Taffe M.A., Weed M.R., Davis S., Huitron-Resendiz S., Schroeder R., Parsons L.H., et al. Functional consequences of repeated (+/-)3,4-methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys. Neuropsychopharmacology 24 (2001) 230-239
71. Taffe M.A., Davis S.A., Yuan J., Schroeder R., Hatzidimitriou G., Parsons L.H., et al. Cognitive performance of MDMA-treated rhesus monkeys: sensitivity to serotonergic challenge. Neuropsychopharmacology 27 (2002) 993-1005
72. Taffe M.A., Lay C.C., Von Huben S.N., Davis S.A., Crean R.D., and Katner S.N. Hyperthermia induced by 3,4-methylenedioxymethamphetamine in unrestrained rhesus monkeys. Drug Alcohol Depend 82 (2006) 276-281
73. Tanner-Smith E.E. Pharmacological content of tablets sold as "ecstasy": results from an online testing service. Drug Alcohol Depend 83 (2006) 247-254
74. Teng S.F., Wu S.C., Liu C., Li J.H., and Chien C.S. Characteristics and trends of 3,4-methylenedioxymethamphetamine (MDMA) tablets found in Taiwan from 2002 to February 2005. Forensic Sci Int 161 2-3 (2006 Sep 12) 202-208 [Electronic publication ahead of print 2006 Jul 13]
75. Upadhyaya H.P., Rose K., Wang W., O'Rourke K., Sullivan B., Deas D., et al. Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults. J Child Adolesc Psychopharmacol 15 (2005) 799-809
76. Von Huben S.N., Davis S.A., Lay C.C., Katner S.N., Crean R.D., and Taffe M.A. Differential contributions of dopaminergic D1- and D2-like receptors to cognitive function in rhesus monkeys. Psychopharmacology (Berl) 188 4 (2006 Nov) 586-596 [Electronic publication 2006 Mar 15]
77. Von Huben S.N., Lay C.C., Crean R.D., Davis S.A., Katner S.N., and Taffe M.A. Impact of ambient temperature on hyperthermia induced by (+/-)3,4-methylenedioxymethamphetamine in rhesus macaques. Neuropsychopharmacology 32 (2007) 673-681
78. White S.R. Amphetamine toxicity. Semin Respir Crit Care Med 23 (2002) 27-36
79. White B., Day C., Degenhardt L., Kinner S., Fry C., Bruno R., et al. Prevalence of injecting drug use and associated risk behavior among regular ecstasy users in Australia. Drug Alcohol Depend 83 (2006) 210-217
80. Wilens T.E., Gignac M., Swezey A., Monuteaux M.C., and Biederman J. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 45 (2006) 408-414
81. Wu L.T., Schlenger W.E., and Galvin D.M. Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths. Drug Alcohol Depend 84 1 (2006 Sep 1) 102-113 [Electronic publication ahead of print 2006 Feb 17. Erratum in: Drug Alcohol Depend 2007 Jan 12;86(2-3):301]
82. Wu LT, Pilowsky DJ, Schlenger WE, Galvin DM. Misuse of methamphetamine and prescription stimulants among youths and young adults in the community. Drug Alcohol Depend in press. [Electronic publication ahead of print 2007 Jan 23].
83. Yuan J., Hatzidimitriou G., Suthar P., Mueller M., McCann U., and Ricaurte G. Relationship between temperature, dopaminergic neurotoxicity, and plasma drug concentrations in methamphetamine-treated squirrel monkeys. J Pharmacol Exp Ther 316 (2006) 1210-1218
84. Zhu B.L., Ishikawa T., Quan L., Li D.R., Zhao D., Michiue T., and Maeda H. Evaluation of postmortem serum calcium and magnesium levels in relation to the causes of death in forensic autopsy. Forensic Sci Int 155 (2005) 18-23